small medium large |  
print   |   Bookmark & Share share

von Hippel-Lindau Disease Clinic

John Heiss, M.D., Clinic Director

Patients with von Hippel-Lindau disease (VHL) and central nervous system tumors (hemangioblastomas and endolymphatic sac tumors) are evaluated, treated and followed in the clinic. Information from clinical, imaging, laboratory and pathologic tissue from patients with VHL is used to develop deeper insights into VHL tumor biology, therapeutic targets, optimal timing of treatment and improved therapies. 

For more information contact: Gretchen Scott, R.N. at gretchen.scott@nih.gov.